The MPRINT Hub is bringing together top researchers from IU and other research institutions across the United States. In addition to this groundbreaking research, we’re working closely with partner organizations, foundations, and agencies.
The overarching goals of the Best Pharmaceuticals for Children Act are:
Funding has been granted to the MPRINT Hub’s research in part by the Bill & Melinda Gates Foundation. The Foundation continues to fund global initiatives working to discover innovative new therapies for mothers and children.
GHMRC exists to promote excellence in breastmilk and breastfeeding research with interdisciplinary collaborations that challenge the science, push the boundaries of knowledge, and contribute meaningfully to the UN Sustainable Development Goals.
GHMRC consists of five independent research centers, based at renowned universities, and endowed by the Family Larsson-Rosenquist Foundation (LRF).
LRF Mother-Milk-Infant Center of Research Excellence at the University of California San Diego
Beyond their individual research areas, the centers are collaborating on interdisciplinary research projects capable of bridging traditional divides between disciplines. As a cornerstone of that interdisciplinary approach, the GHMRC has launched a multi-year fellowship program to connect the different centers. The fellowship program will be announced shortly.
The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network is a global collaboration of investigators, institutions, community representatives, and other partners organized for the purpose of evaluating prevention and treatment interventions for human immunodeficiency virus (HIV) and HIV-associated complications and co-morbidities, including tuberculosis (TB), in infants, children, adolescents, and pregnant and postpartum people through the conduct of high quality clinical trials. IMPAACT’s vision and overall goal is to end the worldwide HIV epidemic among these populations. To achieve this goal, the IMPAACT Network evaluates novel and durable treatments for both HIV and TB, strategies for antiretroviral treatment (ART)-free remission, and strategies to address the complications and co-morbidities affecting these populations of interest living with or affected by HIV. Overall support and funding for IMPAACT is provided by the National Institute of Allergy and Infectious Diseases (NIAID), with support and co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and the National Institute of Mental Health (NIMH), all components of the United States National Institutes of Health (NIH).
Under the Best Pharmaceuticals for Children Act (BPCA), the Pediatric Trials Network (PTN) studies the formulation, dosing, efficacy, and safety of drugs and the development of medical devices used in pediatric patients. PTN provides the Food and Drug Administration (FDA) with information to inform label changes with the necessary information to prescribe the most appropriate doses of medications to children. PTN generates evidence to take the guesswork out of dosing commonly used medications from premature infants to adolescents.
The Foundation for the National Institutes of Health connects world-leading NIH researchers with the ingenuity and expertise of public and private partners to accelerate medical breakthroughs. Building on a more than 25-year track record of success, FNIH partners to solve some of the world’s most complex health challenges. FNIH builds bridges to medical breakthroughs because all people deserve the opportunity to live longer, healthier lives.
The FNIH will partner with the MPRINT hub on a pre-eclampsia initiative, as well as on additional long-term collaborations that jumpstart translational research in maternal health through public-private partnerships.
Critical Path Institute’s International Neonatal Consortium (INC) is a public-private partnership of diverse stakeholders that engages the global neonatal community – families, neonatal nurses, academic scientists, regulators (FDA, EMA, PMDA, Health Canada, and others), pharmaceutical investigators, advocacy organizations, and funders – to focus on the needs of the neonate. Through teams that share data, knowledge, and expertise, INC advances medical innovation and regulatory science for this underserved population to accelerate the development of safe and effective therapies for neonates.
